Kenya
Market Overview Population: Approximately 56 million (2024), the largest economy in East Africa Healthcare System: Public healthcare system (countylevel and national hospitals) + p...
Updated: 2026-05-04
Core regulatory research is publicly available. The page date is a content record; verify the latest regulator requirements before filing.
FDA / CE / MDSAP / NMPA benefits for this market
These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.
US FDA
510(k) / De Novo / PMAModerate benefitFDA evidence is useful technical and clinical support, but the local authority still performs an independent review.
- Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
- May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
- Does not remove local holder, language, labeling, fee, import, or post-market obligations.
EU CE
MDR / IVDRStrong benefitCE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.
- Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
- Often helps build CSDT, IMDRF, or local-format technical files faster.
- Does not replace local registration or local representative responsibilities outside the CE-recognized route.
MDSAP
Single QMS auditIndirect QMS signalMDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.
- Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
- Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
- Does not authorize product sale and does not replace safety, performance, or clinical evidence.
China NMPA
China registration / filingSupportive evidenceNMPA approval can serve as prior-market evidence and a commercial credibility signal, especially for China-made products.
- Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
- Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
- Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
Official source links cited by this page
Open the primary regulator or government source used by the current research page. These links improve traceability but do not by themselves verify every claim or replace the latest official notice.
- Official Portal: online submission system: PPB eRegulations Portal ()ppb.go.keOpen source
- Official Portal: online submission system: PPB eRegulations Portal ()eregs.ppb.go.keOpen source
AI Citation Summary
- Country: Kenya
- Product line: Medical devices
- Regulator / source: Market Characteristics: A strategic hub for the East Africa region, with distribution networks covering neighboring countries including Uganda, Tanzania, Rwanda, and South Sudan; the high-end private medical market has strong demand for innovative devices; public procurement is centralized through KEMSA (Kenya Medical Supplies Authority); regulatory modernization is ongoing
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: 5. PPB Application Screening: confirms document completeness; typically takes weeks to months
- Key fees: Regulatory route - Which product category, risk class, application type, reliance route, or special pathway applies? - Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations
- Local requirement: Kenya medical-device entry should be separated into PPB / Ministry of Health medical-device registration channels regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Population: Approximately 56 million (2024), the largest economy in East Africa
- Healthcare System: Public healthcare system (county-level and national hospitals) + private healthcare (high-end private hospitals including Aga Khan Hospital, Nairobi Hospital, MP Shah Hospital, etc.); the National Hospital Insurance Fund (NHIF, now restructured as the Social Health Insurance Fund, SHIF) continues to expand coverage; healthcare resources are concentrated in Nairobi and coastal areas
- Market Characteristics: A strategic hub for the East Africa region, with distribution networks covering neighboring countries including Uganda, Tanzania, Rwanda, and South Sudan; the high-end private medical market has strong demand for innovative devices; public procurement is centralized through KEMSA (Kenya Medical Supplies Authority); regulatory modernization is ongoing
- Regulatory Maturity: Medium; the Pharmacy and Poisons Board (PPB) is transitioning toward a modern regulatory authority (renamed the Pharmacy and Poisons Board / Pharmacy Council; regulations continue to be updated); the East African Community (EAC) harmonization framework is being advanced
Market-Entry Logic
Kenya medical-device entry should be separated into PPB / Ministry of Health medical-device registration channels regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.
| Entry layer | Key question | Practical view |
|---|---|---|
| Regulatory route | Which product category, risk class, application type, reliance route, or special pathway applies? | Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations |
| Local execution | Who holds the registration, imports, answers regulator questions, manages safety reporting, and controls renewals or variations? | Contract structure matters because local agents, sponsors, distributors, or licence holders can control practical market access even when the foreign manufacturer owns the product |
| Evidence and economics | What clinical, quality, performance, HTA, pricing, and budget-impact evidence is needed? | Registration evidence and payer evidence should be planned together; otherwise approval may be achieved without reimbursement, tender access, or hospital adoption |
| Channel access | Which payer, hospital, distributor, retail, tender, or private-care channel will create volume? | Start with the channel that matches product value and service burden; premium products often need reference sites before broad tender or retail expansion |
Main Players and Channel Map
| Type | Representative players | Market meaning |
|---|---|---|
| Regulator / review | PPB / Ministry of Health medical-device registration channels | Determines approval route, technical evidence, inspections, labelling, post-market duties, renewals, and variations |
| Payment / procurement | NHIF / Social Health Authority transition, KEMSA, county tenders and private hospitals | Determines reimbursement, tender economics, price ceilings, purchasing lists, and patient affordability |
| Companies / channels | KEMSA suppliers, Nairobi Hospital, Aga Khan University Hospital, MP Shah, county hospitals, local distributors and multinational medtech suppliers | Shows the competitive set, partner universe, distribution power, hospital access points, and local execution benchmarks |
| End users / buyers | Public hospitals, private hospital groups, specialist centers, laboratories, pharmacies, insurers, and regional distributors | Determine adoption, tender volume, reference cases, service expectations, and receivables risk |
Development Trends
- Approval and access are increasingly separate: Technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
- Local execution quality is a major differentiator: Strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk.
- Evidence expectations are rising: Payers and hospitals increasingly ask for comparative clinical value, real-world evidence, budget impact, and operational service data.
- Pricing pressure is structural: UHC reform, county procurement fragmentation, donor-funded procurement, distributor due diligence, East Africa hub potential and foreign-exchange risk are reshaping launch sequencing and product economics.
- Partner control should be managed early: Contracts should protect dossier access, registration ownership, renewal obligations, safety reporting, inventory, and transition rights.
Regulatory Authority
- Competent Authority: Pharmacy and Poisons Board (PPB), operating under the Pharmacy and Poisons Act (Cap 244), subordinate to the Ministry of Health; medical devices are managed through PPB's Medical Devices Registration Department
- Official Portal: https://www.ppb.go.ke; online submission system: PPB eRegulations Portal (https://eregs.ppb.go.ke)
- Key Regulations:
- Pharmacy and Poisons Act Cap 244
- Medical Devices (Registration) Rules (multiple updates; refer to the latest version)
- Kenya Standard KS ISO 13485 (Medical Device Quality Management System standard, published by KEBS)
- East African Community Medical Devices Harmonization Framework (EAC framework; in progress)
- Kenya Bureau of Standards (KEBS): certain product categories require a KEBS Standards Compliance Certificate
Device Classification System
| Local Class | Risk Level | EU Equivalent | FDA Equivalent | Description |
|---|---|---|---|---|
| Class 1 | Low risk | EU Class I / FDA Class I | Simplified registration, basic document requirements | |
| Class 2 | Low-medium risk | EU Class IIa / FDA Class II | Standard registration; Technical File required | |
| Class 3 | Medium-high risk | EU Class IIb / FDA Class II–III | Full technical review | |
| Class 4 | High risk | EU Class III / FDA Class III | Most rigorous review; complete clinical evidence required |
Classification is based on GHTF classification principles (referencing GHTF SG1 documents); IVDs have a separate classification following the GHTF IVD classification framework.
Registration Pathways
Pathway for Foreign Manufacturers
Primary Pathway: Registration Through a Local Authorized Agent / Importer
- The foreign manufacturer selects a Kenyan local authorized agent (Kenya Authorized Agent / Local Representative) holding the relevant licenses issued by PPB
- The manufacturer issues a Letter of Authorization (LOA) to the agent; must be notarized in the country of origin (Apostille recommended)
- The agent creates an account in the PPB eRegulations Portal and submits the product registration application
- Pay the PPB registration application fee
- PPB Application Screening: confirms document completeness; typically takes weeks to months
- Technical Evaluation: PPB internal expert review; Class 3/4 may involve external experts
- Supplementary information (if applicable): PPB issues Queries / Deficiency Letter; must be responded to within the specified timeframe
- PPB Expert Committee Approval
- Issuance of PPB Product Registration Certificate
KEBS Conformity Certificate (Applicable to Certain Product Categories)
- Certain medical device products (especially medical equipment and electrical equipment categories) must additionally obtain a KEBS (Kenya Bureau of Standards) Standards Conformity Assessment (Standards Mark / Import Inspection Mark)
- A test report or Conformity Certificate must be obtained through a KEBS-accredited testing laboratory
- Confirm before registration whether the target product is on the KEBS mandatory standards list
Key Prerequisites
- A Kenyan local authorized agent holding a PPB license is mandatory
- ISO 13485 certificate is mandatory (must be from an IAF-accredited body)
- English documents are accepted directly (no Swahili translation required)
- Existing EU CE or FDA approval can serve as technical support to accelerate PPB review
Registration Dossier Requirements
- ISO 13485 certificate (within validity period)
- Free Sale Certificate (FSC / Certificate of Free Sale), issued and authenticated by the competent authority in the manufacturer's country of origin
- Letter of Authorization (LOA), notarized (Apostille recommended)
- Product description and intended purpose (English)
- Device classification justification (per GHTF classification rules)
- Risk Management documentation summary (compliant with ISO 14971)
- Technical File (required from Class 2; Class 3/4 must be complete)
- Clinical Evaluation Report (Class 2: summary; Class 3/4: complete CER)
- Safety test reports (electrical safety IEC 60601, biocompatibility ISO 10993, etc.)
- Instructions for Use (IFU) in English
- Draft labeling (English; Swahili optional)
- Manufacturer's business license (authenticated)
- Copy of agent's PPB license
- Proof of registration in other markets (FDA 510(k), EU CE — strongly recommended)
- KEBS Conformity Certificate (if applicable)
- IVD additional: analytical performance data, reference interval data
Registration Timelines
| Stage | Official Target | Practical Reference |
|---|---|---|
| Class 1 registration | 3–6 months | 6–12 months |
| Class 2 registration | 6–12 months | 12–18 months |
| Class 3 registration | 9–15 months | 15–24 months |
| Class 4 registration | 12–18 months | 18–30 months |
| PPB administrative review | 4–8 weeks | 2–5 months |
| KEBS Conformity Assessment (if applicable) | 2–4 months | 3–6 months |
| Supplementary information wait (per round) | — | Additional 2–6 months per round |
Practical Note: PPB is advancing system modernization (eRegulations Portal), and actual review efficiency has improved compared to before, but resource limitations and backlogs persist; Class 3/4 devices should allow ample time.
Registration Fees
| Item | Estimated Cost (USD) |
|---|---|
| PPB official registration application fee (Class 1) | $200–$500 |
| PPB official registration application fee (Class 2) | $500–$1,200 |
| PPB official registration application fee (Class 3) | $1,200–$2,500 |
| PPB official registration application fee (Class 4) | $2,500–$5,000 |
| Local agent annual service fee | $3,000–$8,000/year |
| Regulatory consultant / document preparation | $5,000–$15,000 |
| KEBS Conformity Assessment fee (if applicable) | $1,000–$3,000 |
| Document notarization / Apostille fees | $300–$800 |
| Annual maintenance fee (registration certificate) | $1,500–$4,000/year |
Total market entry cost (Class 2 typical pathway): USD 12,000–30,000
Local Representative Requirements
- Mandatory: Yes — a PPB-licensed Kenyan local authorized agent (Kenya Authorized Agent) must be appointed
- Representative Qualifications: Must hold a PPB-issued Importer / Distributor License; must be lawfully registered in Kenya; it is advisable to select an agent with medical device registration experience (familiar with PPB eRegulations Portal operations)
- Registration Certificate Holder Rules: The registration certificate may be issued in the manufacturer's name (with the agent as the contact person) or in the agent's name (depending on the specific application); it is recommended that the authorization agreement clearly specifies certificate ownership and transfer rights to guard against agent change risks
Import Requirements
- Import Permit: Each batch of imports must obtain a PPB Import Permit / Authorization; customs clearance through Kenya Revenue Authority (KRA) requires the registration certificate + Import Permit
- Customs Requirements: Governed by KRA; correct HS code declaration required; import duties (most medical devices at 0%; some categories subject to EAC Common External Tariff / CET); VAT 16% (most medical devices subject to VAT; some essential medical equipment may qualify for exemption)
- Labeling Language: English (one of Kenya's official languages); Swahili is the national language — adding Swahili to retail packaging helps with compliance and market acceptance
Post-Market Surveillance
- Adverse Event Reporting: Local agents must report serious device-related adverse events to PPB; PPB is developing an adverse event monitoring system (Pharmacovigilance & Medical Devices Vigilance); timelines follow PPB guidelines (serious events typically reported within 15–30 days)
- Recall Rules: PPB may issue recall orders; local agents must execute and report progress to PPB; distribution records must be maintained to support recall traceability
- Periodic Safety Reports: PPB requires high-risk devices (Class 3/4) to periodically submit safety updates; specific requirements depend on the registration certificate terms
Renewal Requirements
- Certificate Validity: Typically 5 years (some categories 3 years, as noted on the PPB-issued certificate)
- Renewal Timeline: Submit a renewal application at least 6 months before expiry; initiate preparation 9 months in advance (update ISO certificates, FSC, etc.); sales may continue during the renewal period if an application has been submitted
Special Regulatory Requirements
- UDI: Kenya has not yet formally introduced mandatory UDI requirements; the EAC harmonization framework may incorporate UDI requirements in the future — it is advisable to prepare GS1 UDI registration in advance
- Local Testing: KEBS may require testing at KEBS-accredited laboratories for certain product categories (Market Surveillance Sampling); PPB may require sample submission for confirmatory testing for IVD products
- Special Category Restrictions: Devices incorporating radioactive sources require additional authorization from the Kenya Nuclear Regulatory Authority (KNRA); blood product-related IVDs must be assessed by the Kenya National Blood Transfusion Service (KNBTS); imported hearing aids and ophthalmic equipment should receive special attention regarding PPB-specific requirements
Market Access Channels
- Public Hospital Procurement: Centralized procurement through Kenya Medical Supplies Authority (KEMSA) at the federal level; county government hospitals tender through county procurement committees; the KEMSA price catalog is the pricing reference for the public market; entering the KEMSA supplier list requires pre-qualification (PQ)
- Private Hospitals/Clinics: Aga Khan Health Services, Nairobi Hospital, MP Shah Hospital, Avenue Hospital, and other high-end private hospitals procure high-value devices; Karen Hospital, Gertrude Children's Hospital, and other specialist hospitals have specific procurement needs; the private market has relatively high openness to innovative devices
- Distribution/E-commerce: Through medical device distributor networks centered in Nairobi (covering the country and neighboring countries); some consumables and OTC devices are sold through e-commerce platforms such as Jumia Kenya
- Government Tenders: National-level (KEMSA / Ministry of Health framework procurement) and county-level (47 counties each have procurement processes); international agencies such as UNDP, UNICEF, and the Clinton Health Access Initiative (CHAI) play important roles in public health procurement in Kenya — attention should be paid to their procurement standards (typically requiring WHO PQ or equivalent qualification)
Market Entry Strategy Recommendations
- Recommended Pathway: Use Kenya as the strategic entry point for East Africa — Kenya registration experience and certificates help advance corresponding registrations in Uganda, Tanzania, Rwanda, and South Sudan (some countries accept PPB registration certificates as references); open sales volume first in private hospital markets, then gradually enter the KEMSA public procurement system
- Key Risks:
- EAC harmonization framework progress uncertainty: The East African Community medical device harmonization framework has not yet been fully implemented; member states still maintain independent registration requirements; cross-border registration recognition must be verified country by country
- Agent management: Agent qualifications in the Kenyan market vary widely; verify the validity of their PPB license, cold chain warehousing capability, and distribution network coverage
- KEMSA procurement mechanism reform: KEMSA frequently undergoes internal reforms and procurement process changes; the timing for entering the public market is difficult to predict
- KEBS compliance requirements: Some products require additional KEBS Conformity Assessment; if not planned in advance, market entry may be delayed
- Practical Tips:
- Engage a Kenyan local regulatory consultant familiar with both the PPB and KEBS systems; many companies focus only on PPB registration while overlooking KEBS compliance requirements, resulting in clearance difficulties
- International agency procurement (UNICEF, CHAI, MSF, etc.) accounts for a significant share of Kenya's healthcare market; entering this channel requires WHO PQ (World Health Organization Prequalification) or equivalent qualification — it is recommended that manufacturers with eligible products initiate WHO PQ applications
- Kenya has a vibrant technology startup ecosystem; digital health devices and telemedicine equipment have a rapidly growing market demand — monitor PPB regulatory developments for digital health/SaMD
- For East African regional rollout: Kenya → Uganda (NDDA) → Tanzania (TMDA) → Rwanda (RDB) is the recommended sequence for regional sequential registration
Impact of Existing CE / FDA / NMPA Certificates
Quick Assessment
| Certificate | Acceleration Effect | Key Mechanism |
|---|---|---|
| EU CE (MDR/IVDR) | ⭐⭐⭐ | PPB accepts CE certificates as primary technical document evidence; CE can reduce technical data requirements; positive reinforcement for East Africa regional sequential registration |
| US FDA (510(k)/PMA) | ⭐⭐⭐⭐ | FDA certificates receive high recognition in PPB evaluation; notably beneficial for entering KEMSA public procurement and international agency procurement channels |
| China NMPA | ⭐ | PPB does not recognize NMPA; China-Kenya relations are friendly but no mutual recognition exists |
EU CE (MDR/MDD/IVDR)
- Recognition Mechanism: PPB (Pharmacy and Poisons Board) accepts EU CE certificates as the primary source of technical documentation proof in product registration applications. In PPB's technical review phase, products holding CE certificates are regarded as having undergone internationally recognized technical validation; the review committee correspondingly reduces the depth of independent safety and efficacy verification and the frequency of technical queries. PPB follows the GHTF framework and has high acceptance of Technical Files based on EU technical standards (ISO, IEC) — CE certificates effectively simplify the technical file requirements (especially the Clinical Evaluation Report component for Class 3/4 devices).
- Actual Effect: Products with CE certificates typically reduce technical supplementary information by 1–2 rounds in PPB reviews, shortening the overall review period by approximately 3–6 months. For an East Africa regional sequential registration strategy, Kenya PPB's accepting attitude toward CE is similarly referenced by Uganda (NDDA), Tanzania (TMDA), and Rwanda (RDB) — products registered in Kenya with CE certificates, when advancing registration in East African neighboring countries, find CE certificates having a positive effect in each country's review, creating regional synergy.
- Key Caveats: CE certificates must be within their validity period and from an EU-recognized Notified Body; PPB recommends providing an Apostille-authenticated version of the CE certificate; if KEBS (Kenya Bureau of Standards) Conformity Assessment is also required, KEBS has high acceptance of CE certification EMC/electrical safety test reports, which can reduce additional testing requirements; Arabic/Swahili labeling is not mandatory but adding Swahili to retail packaging is recommended; English labeling is fully compliant for healthcare institution and B2B channels.
US FDA (510(k) / De Novo / PMA)
- Recognition Mechanism: FDA 510(k)/PMA approval is more recognized than CE in PPB evaluation — it is the single foreign certificate with the most positive influence on PPB review among all foreign certificates. PPB's Technical Committee has a high degree of recognition for FDA review standards; FDA approval is viewed as proof that the product has achieved the highest international technical standard. Additionally, holding FDA approval is of particularly important value for entering the KEMSA (Kenya Medical Supplies Authority) public procurement system and international agency procurement channels (UNICEF, UNDP, Clinton Health Access Initiative / CHAI) — these procurement entities explicitly prioritize FDA-approved (or WHO PQ) products in technical evaluations.
- Actual Effect: Products with FDA approval typically enjoy the smoothest review experience in PPB evaluation with the lowest probability of supplementary information requests; for Class 3/4 high-risk devices, FDA + CE dual certificates are the optimal configuration for entering the Kenyan market, simultaneously maximizing advantages at both the review and commercial levels. For entry into the KEMSA procurement list, FDA approval or WHO PQ certification is the most highly valued technical endorsement by procurement committees.
- Key Caveats: FDA documents must be currently valid; for entry into international agency procurement channels (UNICEF, etc.), certain product categories (IVDs, essential medicine-related devices) still require WHO PQ in addition — FDA approval supports but cannot replace WHO PQ applications; PPB Import Permits must be applied for separately from PPB registration certificates, with each batch of imports requiring individual processing — this requirement is independent of which foreign certificates are held.
China NMPA (National Medical Products Administration)
- Recognition Mechanism: PPB does not list China's NMPA as a reference regulatory authority. China-Kenya relations are friendly, with relatively active infrastructure and trade cooperation under the Belt and Road framework, and some Chinese medical aid projects (hospital construction, equipment donations) are active in Kenya; however, these fall under government-to-government bilateral aid frameworks and are entirely independent of PPB's commercial registration process — NMPA certificates do not carry formal exemption effect in routine PPB reviews.
- Actual Effect: No formal acceleration effect. Chinese manufacturers must provide the same complete registration documents as any other foreign manufacturer. NMPA certificates may be submitted as "approved by Chinese regulatory authorities" informational attachments — PPB reviewers will not treat them as a basis for reducing technical review requirements. For KEMSA public procurement and international agency procurement channels, NMPA certificates carry no competitive value; CE or FDA certificates must be used instead.
- Key Caveats: Chinese manufacturers entering Kenya must first obtain EU CE certification, then use the CE certificate to advance PPB registration; eligible products (IVDs, essential medical devices, etc.) should apply for WHO PQ to access KEMSA and international agency procurement channels; Chinese manufacturers' competitive advantage in Kenya primarily comes from price and product suitability — a complete international certification framework is required to enter formal procurement channels.
Practical Recommendations
- CE is the core lever for East Africa regional registration: Using Kenya as the East Africa entry market, CE certificates have a positive effect in Kenya PPB, Uganda NDDA, Tanzania TMDA, and Rwanda RDB — creating "one certificate, multiple markets" regional synergy value; when advancing multi-country registration in East Africa, use CE technical files as a unified foundation and adapt to each country's local requirements
- FDA is the key endorsement for public market and international agency procurement: Kenya's public healthcare market (KEMSA procurement) and international agency procurement in Kenya (UNICEF, UNDP, CHAI) place far greater importance on FDA approval or WHO PQ than on PPB registration certificates alone — manufacturers should treat FDA approval as a strategic investment for entering Kenya's high-value public market channels
- KEBS compliance must be independently planned: Some products must additionally pass KEBS (Kenya Bureau of Standards) Conformity Assessment — this is a requirement independent of PPB registration. CE certification technical files (especially EMC and electrical safety test reports) can typically directly support KEBS evaluation, substantially reducing repetitive testing costs
- WHO PQ as a medium-to-long-term strategic goal: For product categories suitable for WHO PQ (IVDs, essential medical equipment, reproductive health devices, etc.), WHO PQ certification is the highest-level pass for the entire international agency procurement ecosystem in Kenya and East Africa — manufacturers with FDA foundations should simultaneously assess the feasibility of WHO PQ applications
- Monitor PPB new rules for digital health devices: Kenya is the most active market for digital health innovation in East Africa; PPB's regulatory rules for SaMD (Software as a Medical Device) and telemedicine devices continue to be updated — CE MDR software compliance documentation (software lifecycle documentation, cybersecurity requirements, etc.) carries important reference value in PPB reviews
Did this page help you decide the next step?
Need a scope memo for your countries and topics? Sign in to save a structured questionnaire. It is not legal advice.
Create my scope memo